<?xml version='1.0' encoding='utf-8'?>
<document id="18089410"><sentence text="Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report."><entity charOffset="18-28" id="DDI-PubMed.18089410.s1.e0" text="tacrolimus" /><entity charOffset="53-63" id="DDI-PubMed.18089410.s1.e1" text="creatinine" /><entity charOffset="87-97" id="DDI-PubMed.18089410.s1.e2" text="cinacalcet" /><pair ddi="false" e1="DDI-PubMed.18089410.s1.e0" e2="DDI-PubMed.18089410.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18089410.s1.e0" e2="DDI-PubMed.18089410.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18089410.s1.e0" e2="DDI-PubMed.18089410.s1.e2" /><pair ddi="false" e1="DDI-PubMed.18089410.s1.e1" e2="DDI-PubMed.18089410.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18089410.s1.e1" e2="DDI-PubMed.18089410.s1.e2" /></sentence><sentence text="Cinacalcet is a calcimimetic drug that has been approved for treatment of secondary and tertiary hyperparathyroidism in patients with renal failure requiring renal replacement therapy"><entity charOffset="0-10" id="DDI-PubMed.18089410.s2.e0" text="Cinacalcet" /></sentence><sentence text=" A few cases of successful treatment in renal transplant patients immunosuppressed with cyclosporine have been reported"><entity charOffset="88-100" id="DDI-PubMed.18089410.s3.e0" text="cyclosporine" /></sentence><sentence text=" Herein we have reported the case of a 48-year-old renal transplant recipient presenting with secondary hypercalcemic hyperparathyroidism (parathyroid hormone [PTH] 896 pg/mL; total calcium, up to 3"><entity charOffset="182-189" id="DDI-PubMed.18089410.s4.e0" text="calcium" /></sentence><sentence text="3 mmol/L) under immunosuppressive therapy with tacrolimus"><entity charOffset="47-57" id="DDI-PubMed.18089410.s5.e0" text="tacrolimus" /></sentence><sentence text=" Owing to substantial comorbidity and a high operative risk, we decided to initiate a therapeutic trial with cinacalcet"><entity charOffset="109-119" id="DDI-PubMed.18089410.s6.e0" text="cinacalcet" /></sentence><sentence text=" Using a daily dose of 30 mg of Cinacalcet, normal calcium levels and a mild fall in PTH levels (decline of 62 pg/mL) were achieved within the first week of treatment"><entity charOffset="32-42" id="DDI-PubMed.18089410.s7.e0" text="Cinacalcet" /><entity charOffset="51-58" id="DDI-PubMed.18089410.s7.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.18089410.s7.e0" e2="DDI-PubMed.18089410.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18089410.s7.e0" e2="DDI-PubMed.18089410.s7.e1" /></sentence><sentence text=" At this point, we also observed a marked decrease in tacrolimus levels (from 6" /><sentence text="3 to 2" /><sentence text="6 mg/dL) without any change in concomitant medications" /><sentence text=" Thus, we adapted the tacrolimus dosage"><entity charOffset="22-32" id="DDI-PubMed.18089410.s11.e0" text="tacrolimus" /></sentence><sentence text=" Concurrent with cinacalcet therapy, there was a rise in serum creatinine levels (from 3"><entity charOffset="63-73" id="DDI-PubMed.18089410.s12.e0" text="creatinine" /></sentence><sentence text="9 to 4" /><sentence text="9 mg/dL before discontinuation of cinacalcet), which was not reversible after termination of 3 weeks of treatment with cinacalcet, but continued"><entity charOffset="34-44" id="DDI-PubMed.18089410.s14.e0" text="cinacalcet" /><entity charOffset="119-129" id="DDI-PubMed.18089410.s14.e1" text="cinacalcet" /><pair ddi="false" e1="DDI-PubMed.18089410.s14.e0" e2="DDI-PubMed.18089410.s14.e0" /><pair ddi="false" e1="DDI-PubMed.18089410.s14.e0" e2="DDI-PubMed.18089410.s14.e1" /></sentence><sentence text=" Cinacalcet and tacrolimus are both metabolized via cytochrome P 450"><entity charOffset="1-11" id="DDI-PubMed.18089410.s15.e0" text="Cinacalcet" /><entity charOffset="16-26" id="DDI-PubMed.18089410.s15.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.18089410.s15.e0" e2="DDI-PubMed.18089410.s15.e0" /><pair ddi="false" e1="DDI-PubMed.18089410.s15.e0" e2="DDI-PubMed.18089410.s15.e1" /></sentence><sentence text=" The documented decrease in tacrolimus serum levels, suggested a drug-drug interaction between tacrolimus and cinacalcet"><entity charOffset="28-38" id="DDI-PubMed.18089410.s16.e0" text="tacrolimus" /><entity charOffset="95-105" id="DDI-PubMed.18089410.s16.e1" text="tacrolimus" /><entity charOffset="110-120" id="DDI-PubMed.18089410.s16.e2" text="cinacalcet" /><pair ddi="false" e1="DDI-PubMed.18089410.s16.e0" e2="DDI-PubMed.18089410.s16.e0" /><pair ddi="false" e1="DDI-PubMed.18089410.s16.e0" e2="DDI-PubMed.18089410.s16.e1" /><pair ddi="false" e1="DDI-PubMed.18089410.s16.e0" e2="DDI-PubMed.18089410.s16.e2" /><pair ddi="false" e1="DDI-PubMed.18089410.s16.e1" e2="DDI-PubMed.18089410.s16.e1" /><pair ddi="false" e1="DDI-PubMed.18089410.s16.e1" e2="DDI-PubMed.18089410.s16.e2" /></sentence><sentence text=" The irreversible deterioration in renal function may be attributed to nephrotoxic properties of cinacalcet, but may also indicate an acceleration of the natural course of chronic allograft nephropathy"><entity charOffset="97-107" id="DDI-PubMed.18089410.s17.e0" text="cinacalcet" /></sentence><sentence text="" /></document>